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Systemic light chain amyloidosis (LCA) is a raremonoclonal
B cell disorder characterized by the accumulation ofmisfolded
monoclonal light chain fragments within the heart, kidney,
liver, gut, peripheral nerves, and other tissues, resulting in
damage to these organs. Median survival is poor (less than
3 years in many series) and most closely associated with the
degree of cardiac involvement [1-5]. However, recent progress
in the diagnosis, characterization, and management of pa-
tients with LCA necessitates thoughtful reassessment of the
role of high-dose chemotherapy in the management of this
challenging disease. For years, the pace of improvement has
been hampered to some degree by the rarity of the condition,
lack of good preclinical models, heterogeneity in clinical pre-
sentation, and less than enthusiastic support from pharma-
ceutical companies and national organizations. Accrual to
prospective clinical trials, critically important to evaluate
several of the newer treatment approaches, has often been
sluggish at many centers or trials have not been available.
Thus, high-dose chemotherapy and autologous hematopoietic
cell transplantation (HCT) continues to be considered a suit-
able frontline therapy for appropriate LCA patients.
The role of high-dose melphalan and HCT in LCA was
initially explored in the early 1990s [6]. Although treatment-
related mortality (TRM) was frighteningly high (>30%) in
these early experiences, long-term survivors enjoying good
quality of life were observed and, eventually, this treatment
became an established part of the amyloidosis therapeutic
armamentarium more than a decade ago [1,7,8]. Notwith-
standing, the only prospective randomized trial completed to
date comparing high-dose therapy to conventional chemo-
therapy failed to demonstrate a beneﬁt for LCA patients who
underwent transplantation early in the course of the disease,
and even suggested they may do worse, with median overall
survival of 22.2 months in the high-dose chemotherapy
group and 56.9 months in the group treated conventionallyedgments on page 18.
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TRM in the group who underwent transplantation (24%) and
the inclusion of patients who underwent transplantation at
centers with little to no experience using high-dose
chemotherapy in patients with LCA [10]. Nevertheless, a
landmark analysis with long-term follow-up failed to
demonstrate an advantage to high-dose chemotherapy, even
in those patients surviving the ﬁrst 100 days of HCT [10].
Further, a subsequent meta-analysis, also heavily criticized,
again failed to demonstrate a beneﬁt to HCT [11,12]. With the
advent of immunomodulatory drugs and proteasome in-
hibitors, hematological response rates and organ function
improvements have increased and demand that we question
the value of high-dose chemotherapy and HCT, even in less
risky patients with LCA, given the availability of effective and
potentially less toxic therapies [5,13].
The greatest number of autologous HCT for patients with
LCA are performed within the United States [14]. Notwith-
standing, the US National Comprehensive Cancer Network
2013 guidelines for treatment of systemic LCA do not make
ﬁrm recommendations for ﬁrst line therapy and instead
include high-dose chemotherapy as 1 of a number of ther-
apeutic considerations for the management of these pa-
tients (all recommendations being category 2a) [15]. They
conclude that “the optimal therapy for systemic LCA still
remains unknown, the National Comprehensive Cancer
Network panel members strongly encourage treatment in
the context of a clinical trial when possible.” Unfortunately,
most patients are either ineligible for or not offered clinical
trials [5,13,16]. So, which patients are appropriate candi-
dates for HCT outside the context of a clinical trial? Should
these patients undergo transplantation only at specialized
centers with signiﬁcant experience providing trans-
plantations for patients with LCA, or is it appropriate for
them to undergo HCT at centers that perform fewer than 5
transplantations for LCA annually? Should there be more
stringent guidelines established for selecting appropriate
candidates, and should each center performing such
transplantations follow established guidelines for all as-
pects of supportive care, including stem cell mobilization
and procurement, chemotherapy administration, and post-Transplantation.
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these questions here.
Many within the amyloidosis treatment community have
questioned the value of high-dose chemotherapy, given the
high risk of TRM and in light of the results of the only ran-
domized study [5,13,17]. As mentioned, the French prospec-
tive study was believed to be highly ﬂawed by several
members of the blood and marrow transplantation com-
munity, who may themselves be biased toward the value of
high-dose chemotherapy [9,10]. Appropriately, issues were
raised about patient selection; the inclusion of high-risk
patients with cardiac involvement, who in retrospect
should probably have been excluded; the lack of inclusion of
biomarkers to predict prognosis; the lack of experience at
many of the participating centers; the dose of melphalan
used; and the protracted length of time required to complete
the study. Many have pointed toward these criticisms to
downplay the signiﬁcance of the study results. In rebuttal,
the study authors performed a follow-up landmark analysis
that accounted for patients who died early after trans-
plantation [10]. This analysis still failed to show an advantage
for patients who had received high-dose melphalan, once
again questioning the overall value of melphalan dose esca-
lation. On the positive side, the ﬁndings forced the trans-
plantation community to reconsider the salient issues and to
better establish guidelines for patient eligibility and sup-
portive care. This has resulted in substantial improvements
in the risk of TRM in recent years [18-21]. Thus, it is
reasonable to re-examine the critical questions that each
center must consider when evaluating the role of high-dose
chemotherapy in the treatment of their patients with LCA.
Much of the current decision making requires a clear un-
derstanding of the goals of therapy, a comprehensive
assessment of the extent of disease in any 1 individual, and
based on that, the overall prognosis and degree of risk of
morbidity and mortality related to the primary therapy
chosen [13,17-19,21-24]. An extensive discussion of the
pathophysiology of LCA, as well as its diagnosis and man-
agement, is beyond the scope of this review, but the reader is
referred to several excellent recent reviews covering these
topics [3-5,7,13,16,25-32].
WHAT ARE THE PRIMARY GOALS OF THERAPY
IN THIS DISEASE?
Systemic therapy designed to destroy the plasma cell
clones responsible for the synthesis of immunoglobulin light
chain remains the primary approach [1,7,13,20,21,29,33-40].
The goal is to promptly eradicate the misfolded amyloid light
chains, resulting in improvement in the function of the
involved organ(s). The importance of a good hematological
response has beenwell established over the last several years
[13,38]. Hematological response (HR) is considered essential
for the establishment of an organ response, although HR
does not always translate into organ improvement.
Consensus criteria have been developed for the assessment
of HR and organ response [37]. The inclusion of the serum-
free light chain assay has greatly improved the assessment
of HR, as has the use of cardiac biomarkers such as cardiac
troponin and NT-proBNP [41,42]. As is the case with multiple
myeloma, there is some controversy as to whether a com-
plete HR is necessary for long-term clinical beneﬁt, particu-
larly if organ response is observed and organ dysfunction is
stabilized or improved [5,13,16,38,40,43]. Notwithstanding,
long-term responses have been seen, particularly in patients
achieving a complete response to high-dose chemotherapy[43]. In addition to depth of response, the rapidity of
response is also an important factor inﬂuencing the likeli-
hood of achieving organ stabilization or improvement.
Achievement of a rapid HR certainly pertains to patients
receiving high-dose chemotherapy, but it is also relevant
when one considers nontransplantation therapies and the
decision to use a regimen containing immunomodulatory
agents (eg, thalidomide, lenalidomide, or pomalidomide)
versus a proteasome inhibitor (bortezomib, carﬁlzomib)
[5,13,16,18,44-55]. Data suggest HR and even organ re-
sponses may be observed more rapidly with regimens
incorporating a proteosome inhibitor [5,49,50]. The addition
of bortezomib may improve the rapidity of response and is
currently being studied in a randomized prospective trial
comparing bortezomib added to standard melphalan and
dexamethasone [46,51,56,57]. Whether the addition of
cyclophosphamide to bortezomib and dexamethasone im-
proves the depth and rapidity of response remains an open
question, but many of the best responses have been seen
with the so-called CyBorD (cyclophosphamide, bortezomib,
and dexamethasone) regimen [49,51]. As with multiple
myeloma, numerous combinations of novel agents are
currently being evaluated in patients who are not considered
candidates for HCT, but may also prove effective in patients
traditionally considered for high dose chemotherapy as pri-
mary treatment.
Older studies failed to establish the beneﬁt of induction
chemotherapy before high-dose chemotherapy and HCT in
LCA, but given the availability of potentially better induction
regimens that work rapidly, the value of both induction and
consolidation chemotherapy in the context of high-dose
chemotherapy is being revisited in ongoing clinical trials
[7,16,58,59]. Most would agree that depth of response in-
ﬂuences the potential for prolonged survival and should also
translate into an improved quality of life. This remains to be
established prospectively. For those who would advocate
high-dose chemotherapy, depth of response is the critical
factor in establishing an overall beneﬁt in these patients
[16,43].
WHAT ROLE HAS PATIENT SELECTION PLAYED IN THE
FAVORABLE OUTCOMES OBSERVED AFTER HCT?
Patient selection exerts a profound inﬂuence on treat-
ment outcome in virtually any clinical trial setting. Given the
very high rates of TRM (particularly within 100 days of
transplantation) reported in the early trials, which estab-
lished a role for high-dose melphalan in the treatment of
LCA, it is hard to imagine that the pioneering centers were
“cherry picking” the best patients [6,58-61]. Much was
learned through these preliminary explorations of high-dose
chemotherapy. Early on, and not surprisingly, it became clear
that the number and extent of organ involvement, patient
age, performance status, and, in particular, the severity of
cardiac involvement exerted a heavy inﬂuence on the risk
of TRM [6,58-61]. Retrospective analyses demonstrated
that many of the early deaths were in patients with the
most severe cardiac involvement and established the basic
tenet that patients with very advanced cardiac involvement
should probably not undergo high-dose chemotherapy
[1,2,11,20,21,29]. However, even that statement has been
questioned by recent data from theMayo Clinic [7,29,47]. The
establishment of the Mayo staging system has provided a
universally accepted method for evaluating patient charac-
teristics across centers [24]. The use of cardiac biomarkers
(troponin, NT-proBNP) before HCT has provided the most
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inclusion and/or exclusion from high-dose chemotherapy. A
recent report fromMayo Clinic established that patients with
NT-proBNP levels greater than 5000 pg/mL should not un-
dergo HCT given their extremely high risk of TRM [47]. The
use of serum biomarkers provides a more objective means to
predict a patient’s risk and to compare results across studies
rather than number of organs involved, given the potential
variability in assessing organ involvement from center to
center. Beyond risk of TRM, recent data also suggest that the
extent of bone marrow plasma cell involvement heavily in-
ﬂuences the likelihood of long-term survival, and patients
with greater than 10%marrow plasma cell involvement seem
to have worse overall survival [62-64].
The issue of TRM (as high as 30% in some series) becomes
even more important now that there are other potentially
effective therapies available to these patients [5,7,13]. So,
what should be considered an acceptable rate of TRM, at least
within the ﬁrst 100 days of transplantation? Clearly, rates
above 10% seem unacceptably high except for certain
exceptional situations. It would seem reasonable that rates
approaching those observed with other hematological ma-
lignancies amenable to autografting (<5%) should be the
goal. However, if such stringent criteria are used, the vast
majority of patients are unlikely to be candidates for HCT,
even at the experienced transplantation centers using well-
established supportive care guidelines. It has been esti-
mated that nomore than 20% to 30% of all patients diagnosed
with primary LCA would be eligible for upfront HCT if the
goal is to maintain a low risk of TRM [5,13,16]. From the
perspective of this reviewer, the availability of potentially
effective conventional therapies necessitates that we accept
only a low risk of TRM. Given these concerns, randomized
prospective trials comparing HCT with conventional regi-
mens are even more urgently needed than before, but they
are unlikely to be performed. For instance, a recent trial in
the United Kingdom comparing cyclophosphamide, thalid-
omide, and dexamethasone to high-dose chemotherapy was
closed because of lack of accrual [5]. Whether this was due to
the lack of equipoise on this issue or other matters in unclear.
In the United States, where the majority of upfront trans-
plantations are performed, there are currently no plans for a
prospective trial comparing high-dose to more conventional
chemotherapy. Unfortunately, this leaves both patients and
the physicians caring for them in a quandary over the best
initial approach. A conservative management approach
would be to embark initially on a less toxic, better tolerated
conventional regimen ﬁrst, to be followed by high-dose
chemotherapy if certain response goals are not met. This
approach has recently been advocated by some, but it could
be risky if a patient then misses the opportunity to beneﬁt
from high-dose chemotherapy [5]. In the absence of clinical
trials, the Mayo Clinic guidelines for selecting trans-
plantation candidates should be adopted by most centers
until better treatments are available [47].
IF THE DECISION HAS BEEN MADE TO MOVE FORWARD
WITH HIGH-DOSE CHEMOTHERAPY, ARE THERE
ESTABLISHED “BEST PRACTICES” FOR THE
MANAGEMENT OF THESE PATIENTS? DOES CENTER
EXPERIENCE MATTER AND, IF SO, HOW MUCH?
Fortuitously, the centers with the greatest longitudinal
experience in providing transplantations to patients with
LCA have developed and published guidelines to mitigate the
risk of morbidity and mortality throughout the process ofstem cell mobilization and procurement and after high-dose
chemotherapy [1,2,16,18,29,31,58]. At both the Mayo Clinic
and Boston University, TRM has markedly improved over the
last several years, based on experience in supporting these
patients, as well as on the establishment of better selection
criteria [2,43,47]. Typically these go hand in hand. Centers
performing fewer than 5 to 10 transplantations annually for
amyloidosis are well advised to follow guidelines established
by these larger programs. A recent review of registrations to
the Center for International Blood and Marrow Transplant
Research determined that the majority of centers in the
United States that perform transplantations in patients with
LCA do so in less than 5 patients annually (Marcelo Pasquini,
personal communication). At Ohio State University, where
we perform transplantations on no more than 5 LCA patients
annually (but perform 80 to 100 multiple myeloma auto-
grafts yearly), we have carefully reviewed the Mayo Clinic
and Boston University experiences, adopted many of their
practices, and have developed our own criteria for support-
ing patients through stem cell mobilization and procure-
ment, determining the dosage of melphalan, and the use of
blood product and growth factor support after peripheral
blood cell stem cell transplantation (PBCT). The outcomes for
these patients are continuously reviewed at our site, and
guidelines are revised according to outcomes, based on a
process of continuous quality improvement. Based on a
combination of strict selection criteria and stringent sup-
portive care guidelines, only 1 of 29 LCA patients undergoing
PBCT at our center has experienced TRM before day 100
(Yvonne Efebera, unpublished observation).
HOW SHOULD WE MOBILIZE STEM CELLS?
Akin to patients with multiple myeloma, most patients
treated in the early days of transplantation for LCA under-
went stem cell mobilization following high-dose cyclo-
phosphamide [1,6,9,11,60,61,65,66]. Unfortunately, many
patients did not tolerate this approach nearly as well as their
myeloma counterparts, primarily because of a high risk of
mortality, secondary to cardiac events, infection, or bleeding
episodes. Alternative strategies were sought and a shift
towards cytokine-based mobilization using granulocyte
colonyestimulating factor (G-CSF) appears to have substan-
tially lowered substantially the risk of morbidity and mor-
tality during stem cell mobilization [1,2,21,58]. G-CSFebased
mobilization has become the standard method by which
hematopoietic-reconstituting cells are obtained from LCA
patients. Meticulous attention to volume shifts and other
apheresis techniques are critical, as well, as many of these
patients have suffered severe complications during the pro-
cess of leukapheresis. Given that most of these patients have
not received prior chemotherapy or, if they have, it has been
of limited duration, G-CSF should be adequate to mobilize a
sufﬁcient stem cell dose in themajority of these patients. The
presence of amyloid deposition within the bone marrow
does not appear to adversely affect stem cell mobilization
[67]. Plerixafor has been added to G-CSF in a small number of
LCA patients, and its use appears to be safe [68]. However,
plerixafor administration should probably be reserved for
patients failing to mobilize adequately with G-CSF alone.
Because the use of tandem transplantation has not been
established in patients with LCA, sufﬁcient hematopoietic
progenitor cells to support 1 course of high-dose chemo-
therapy is generally adequate [58,66]. However, given con-
cerns about added toxicity with the routine use of G-CSF post
transplantation, it may bewise to procure at least 4 to 5106
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neutrophil recovery in the absence of G-CSF use after HCT.
The optimal CD34 dose for infusion following high-dose
melphalan in LCA patients has not been well established.
WHAT IS THE APPROPRIATE MELPHALAN DOSE AND
SHOULD THAT DOSE BE PATIENT SPECIFIC?
The prospective French randomized trial used melphalan
200 mg/m2 as the standard dose, with reduction to 140 mg/
m2 for older patients and for those with poor cardiac or renal
function [9]. Others have advocated for adjustments in the
dose of high-dose melphalan, based on the presence or
absence of organ involvement and/or age, with doses ranging
from 100 mg/m2 to 200 mg/m2 reported in the published
studies [18-20,22]. Given that hematological response may
be related to dose received, there is a potential downside
with the use of doses reduced to levels lower than typically
used in multiple myeloma. This is once again controversial,
particularly now that the ultimate beneﬁt of high-dose
melphalan in LCA is being questioned. Further, the pharma-
cology of high-dose melphalan in patients with LCA has not
been well studied. In multiple myeloma patients, there are
data to suggest that pharmacogenomic factors may signiﬁ-
cantly inﬂuence exposure to high-dose melphalan [69]. At
Ohio State University, a pharmacogenomics study inmultiple
myeloma is ongoing. We hypothesize that there may be
important differences inmelphalan handling among patients
and that toxicity may be related either to peak concentra-
tions achieved or, alternatively, to area under the curve and
that, perhaps, melphalan may be better dosed based on
measured or predicted pharmacokinetics, similar to dosing
for busulfan. This may be even more important in LCA pa-
tients, given the high risk of TRM. In this high-risk group of
patients, it would be interesting to consider individualized
dosing of melphalan based not only on clinical characteristics
such as age, renal function, and cardiac reserve, but also
based on pharmacogenetics. The value of pursuing this
strategy further will ultimately rest with the issue of
whether any dose escalation of melphalan is warranted.
The role of other types of high-dose chemotherapy drugs
for conditioning, the addition of other drugs, such as borte-
zomib, to a melphalan-based conditioning regimen, and the
use of other approaches, such as total body irradiation, have
been reported mainly from single centers with varying de-
grees of success [46,58,59,70]. Total body irradiation seems
excessively toxic in these patients [70]. However, no ﬁrm
recommendations can be made and it seems that high-dose
melphalan alone should remain the baseline conditioning
regimen outside the context of a clinical trial.
IS THERE A ROLE FOR CONSOLIDATION AND
MAINTENANCE AFTER TRANSPLANTATION, AS THERE IS
FOR MULTIPLE MYELOMA?
Depth of response is associated with beneﬁt from high-
dose chemotherapy, and data from multiple myeloma pa-
tients suggest that depth of response can be improved with
both consolidation and maintenance treatment after auto-
graft. Thus, there are currently studies evaluating the use of
consolidation andmaintenance strategies in LCA patients not
achieving complete response after 1 course of high-dose
melphalan [5,16,46,71]. Clearly, issues related to tolerability
are paramount, but given the availability of immunomodu-
latory drugs and proteasome inhibitors that have been
relatively well tolerated, the question is, indeed, relevant.
One study from Memorial Sloan Kettering suggestedconsolidation with bortezomib was both feasible and effec-
tive in this setting [46]. Others have reached similar con-
clusions [16]. Outside the context of a clinical trial, the use of
maintenance treatment, particularly with a drug like lenali-
domide, which has been associated with a potentially higher
risk of secondary malignancies, should be considered on a
case-by-case basis and the pros and cons discussed in detail
with the patient [71,72]. There are insufﬁcient data at present
to make any ﬁrm recommendations regarding maintenance
treatment in LCA after high-dose chemotherapy.
HOW MUCH GUIDANCE CAN WE EXPECT FROM
ONGOING CLINICAL TRIALS?
It seems as if most manuscripts published on the topic of
treatment of systemic LCA incorporate the conclusion that
prospective clinical trials are urgently needed. It is certainly
difﬁcult to argue with this conclusion, but what is the evi-
dence that sufﬁcient clinical trials are available or that they are
relevant to the majority of patients diagnosed with LCA? A
recent review of the Clinicaltrials.gov database (performed on
September 22, 2013), searching for either phase II or III trials
involving patients with systemic LCA, revealed a total of 8
phase II and 2 phase III studies. The pace of progress in this
disease may remain slow as a result, particularly given the
current NIH funding climate. Unfortunately, a number of
prospective trials have had to close because of poor accrual.
Whether this is due to study design issues, feasibility, lack of
relevance for themajority of LCA patients seen in practice, the
advancednature of disease inmany newlydiagnosed patients,
lack of publicity, or other factors is unclear. However, the
dearth of available trials represents a signiﬁcant impediment
toward further progress in the treatment of this very difﬁcult
disease. At a minimum, reports of experience with high-dose
therapy should include results not only for the patients who
hadunderwent transplantation, but also for those inwhoman
unsuccessful effort was made to procure cells that could be
used for transplantation. The prospective French study
accounted for both groups, but many retrospective reports
have included results only for patients who underwent
transplantation and did not account for the complications
associated with unsuccessful stem cell mobilization [9].
PUTTING IT ALL INTO CONTEXT: WHAT IS THE ROLE OF
HIGH-DOSE CHEMOTHERAPY IN 2014?
The role of high-dose chemotherapy remains unclear,
particularly for thosepatientswithLCAwhomaybedeemedto
be at anything more than a low risk for mortality related to
high-dose melphalan. It is difﬁcult to discount the fact that
many LCA patients have enjoyed prolonged progression-free
survival with good quality of life after high-dose chemo-
therapy and autologousHCT [13,16,43]. Clearly, themajority of
patients newly diagnosed with LCA are not candidates for
high-dose chemotherapy. Among the estimated 20% to 30% of
patients who have a low enough risk of TRM to be considered
for this procedure, who are best treated with this approach?
Patients should be placed on prospective clinical trials when-
ever possible. Patients with newly diagnosed LCA should be
considered for referral to centers focusing on this disease.
When that is not possible, patients should be referred to and
placed on LCA-speciﬁc clinical trials approved at local/regional
NCI-designated cancer centers within the United States,
whenever possible. A clinical trial, whether evaluating con-
ventional or high-dose chemotherapy as a strategy, would be
preferable to high-dose chemotherapy performed outside of a
clinical trial. Clearly not everyone would agree, and
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will either not be offered a clinical trial or will not be eligible.
For those who would be eligible for a clinical trial but cannot
participate or choose not to participate, high-dose chemo-
therapy shouldbeoffered to thosepatientswilling to acceptup
to 5% to 10% risk of TRM within the ﬁrst 100 days after trans-
plantation. Such patients should be deemed ﬁt and good
candidates based on criteria established at the large referral
centers. Preferably, patientswould undergo transplantation at
centers that perform 5 to 10 or more transplantations for this
disease annually, although this is admittedly an arbitrary
number. Each center willing to offer HCT to a patient with LCA
should, if theyhavenot already, adoptwell-establishedcriteria
for transplantation candidacy and should strongly consider
the development of LCA-speciﬁc supportive care guidelines
within their center for every aspect of the procedure, from
stem cell mobilization to supportive care, within the ﬁrst 3 to
4 months after HCT.
The United States’ blood and marrow transplantation
community should consider clarifying the role of PBCT in LCA.
The feasibility of a prospective trial supported by the US gov-
ernment, perhaps by the NIH-funded Blood and Marrow
Transplant Clinical Trials Network, should be seriously
considered. Unfortunately, given the rarity of this disorder and
heterogeneity of the patients at diagnosis, together with the
low proportion of patients eligible, such a study may not be
feasible, particularly if overall survival were chosen as the pri-
mary endpoint. Short of that, consistent registration of LCA
patients undergoing transplantation at centers within the
Center for InternationalBloodandMarrowTransplantResearch
should be mandatory, and outcomes at individual centers
should be scrutinized closely, particularly because many cen-
ters perform fewer than 5 transplantation in these patients
annually (Marcelo Pasquini, personal communication). The use
of cardiacandotherbiomarkers to establishcandidacy forhigh-
dose chemotherapy should become the standard of care
throughout centers and establishment of newer biomarkers
and genetic signatures should continue to be pursued.
After more than 20 years of studying the role of high-dose
chemotherapy in LCA, much has been learned.We knowwho
should probably not undergo transplantation, and we know
that there is certainly a signiﬁcant fraction of patients who
derive long-term beneﬁt from this approach. Better precision
in the identiﬁcation of those LCA patients who derive long-
term beneﬁt from high-dose chemotherapy in preference
to less toxic therapies should be a major goal in the next
decade, as should continued improvement in supportive
care, such that LCA patients undergoing HCT do not suffer
rates of TRM substantially higher than their counterparts
with multiple myeloma.
With the advent of novel therapies, it remains unclear
whether high-dose chemotherapy will maintain an estab-
lished role in the planned upfront therapy of LCA or if its use
will be relegated to a treatment for patients who have failed
to respond to 1 or a number of more conventional and less
toxic therapies. This is conceivable, given the recent devel-
opment of novel therapies, including antibody treatments
and methods to absorb amyloid ﬁbrils, which hold promise
for the future [73-76].ACKNOWLEDGMENTS
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